<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798406</url>
  </required_header>
  <id_info>
    <org_study_id>2401BT-002P</org_study_id>
    <nct_id>NCT02798406</nct_id>
  </id_info>
  <brief_title>Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects</brief_title>
  <acronym>CAPTIVE</acronym>
  <official_title>A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DNAtrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DNAtrix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant
      brain tumor in adults and can be resistant to conventional therapies. The purpose of this
      Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds
      to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered
      directly into the tumor followed by the administration of intravenous pembrolizumab (an
      immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease
      progression.

      Funding Source-FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the initial phase of the study, up to 12 evaluable subjects will be enrolled in 3 dose
      cohorts to determine the best dose of DNX-2401, as follows:

        -  Cohort 1: Single dose DNX-2401 (5e8 vp) delivered intratumorally by cannula, followed by
           intravenous pembrolizumab every 3 weeks (Q3W)

        -  Cohort 2: Single dose DNX-2401(5e9 vp) delivered intratumorally by cannula, followed by
           intravenous pembrolizumab every 3 weeks (Q3W)

        -  Cohort 3: Single dose DNX-2401 (5e10 vp) delivered intratumorally by cannula, followed
           by intravenous pembrolizumab every 3 weeks (Q3W)

      Following the initial phase, up to 36 additional subjects diagnosed with recurrent
      glioblastoma or gliosarcoma will be enrolled to receive a single of DNX-2401 determined in
      the initial phase administered intratumorally followed by intravenous pembrolizumab every 3
      weeks.

      All subjects will return to the clinic for study follow-up visits at regular intervals for
      safety monitoring, MRI scans and other assessments, for up to 2 years or until disease
      progression. All subjects will be followed closely for safety and survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Interval tumor size reduction as measured from periodic MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months alive following treatment as measured during periodic study visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor response</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months to response following treatment as measured during periodic MRIs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months of sustained response as measured during periodic study visits</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Brain Neoplasm</condition>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <condition>Malignant Brain Tumor</condition>
  <condition>Neoplasm, Neuroepithelial</condition>
  <condition>Neuroectodermal Tumors</condition>
  <condition>Neoplasm by Histologic Type</condition>
  <condition>Neoplasm, Nerve Tissue</condition>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNX-2401</intervention_name>
    <description>On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.</description>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <other_name>Oncolytic virus</other_name>
    <other_name>Genetically-modified adenovirus</other_name>
    <other_name>Delta-24</other_name>
    <other_name>Delta-24-RGD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401</description>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <other_name>KEYTRUDA</other_name>
    <other_name>lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
    <other_name>Checkpoint inhibitor</other_name>
    <other_name>monoclonal antibody</other_name>
    <other_name>anti-PD1/PD-L1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A single glioblastoma or gliosarcoma tumor with histopathological confirmation for
             first or presenting second recurrence of glioblastoma or gliosarcoma at the time of
             consent

          -  Gross total or partial tumor resection is not possible or not planned

          -  A single measurable tumor that is at least 10.0 mm longest diameter (LDi) X 10.0 mm
             shortest diameter (SDi) and this tumor does not exceed 40.0 mm in LDi or SDi

          -  Tumor recurrence or progression documented after previously failing surgical
             resection, chemotherapy and/or radiation

          -  Karnofsky performance status ≥ 70 %

          -  Prior anti-tumor therapies must have been completed within time periods specified in
             the protocol prior to DNX-2401 injection

        Exclusion Criteria:

          -  Multiple (≥ 2) separate enhancing tumors

          -  Tumor location on both sides of the brain and/or involvement that would present the
             risk of injecting DNX-2401 into the ventricles of the brain

          -  Tumor location in the brain stem

          -  Requires treatment with high-dose systemic corticosteroids within 2 weeks of the start
             of intravenous pembrolizumab infusions

          -  Uncontrolled blood-sugar levels defined as HbA1c &gt; 7% on 2 separate measurements

          -  Previous treatment with anti-PD1 or PD-L1 agents including pembrolizumab (KEYTRUDA) or
             any other checkpoint inhibitor(s) (e.g., ipilimumab, nivolumab, etc.)

          -  Evidence of active, non-infectious pneumonitis and/or a history of interstitial lung
             disease

          -  Prior gene transfer therapy or prior therapy with a cytolytic virus of any type

          -  Brain tumor that is not measurable on MRI or persons who are unable to have MRIs

          -  Pregnant or nursing females

        Note: Other protocol-defined inclusion and exclusion criteria may apply as outlined in the
        relevant protocol version
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Tufaro, PhD</last_name>
    <role>Study Director</role>
    <affiliation>DNAtrix, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences (UAMS)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candi Langmaid</last_name>
      <phone>501-686-8274</phone>
      <email>CALangmaid@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kacie Simpson</last_name>
      <phone>501-686-8274</phone>
    </contact_backup>
    <investigator>
      <last_name>Shirley S Ong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emese Filka</last_name>
      <phone>310-794-3521</phone>
      <email>efilka@mednet.ucla.net</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Green, NP</last_name>
      <phone>310-825-0644</phone>
      <email>SDGreen@mednet.ucla.net</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Cloughesy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Lukas</last_name>
      <phone>312-695-1371</phone>
      <email>rachel.lukas@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Kloeppinger</last_name>
      <phone>312926-6585</phone>
      <email>lauren.kloeppinger@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Priya Kumthekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Jackson, B.S.</last_name>
      <phone>732-235-9427</phone>
      <email>clarkce@cinj.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Jackson</last_name>
      <phone>732-235-9835</phone>
      <email>jacksoka@cinj.rutgers.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert D Aiken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariza Daras (Brain Tumor Line), MD</last_name>
      <phone>212-639-6767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill-Cornell Medicine New York-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyson Hignight</last_name>
      <phone>212-746-1788</phone>
      <email>alh2031@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary O'Hehir</last_name>
      <phone>212-746-7373</phone>
      <email>mao2037@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rohan Ramakrishna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Schilero</last_name>
      <phone>216-636-9410</phone>
      <email>schilec@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Allison</last_name>
      <phone>216-444-6459</phone>
      <email>allisot@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Vogelbaum, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Osman</last_name>
      <phone>614-685-2435</phone>
      <email>Nadia.Osman@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barb Kleiber</last_name>
      <phone>614-2931815</phone>
      <email>Barbara.Kleiber@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vinay Puduvalli, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Candelo, RN, BSN</last_name>
      <phone>610-402-0636</phone>
      <email>Yasmin_o.candelo@lvhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Dana E. Clark</last_name>
      <phone>610-402-9543</phone>
      <email>Dana_E.Clark@lvhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Suresh Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin-Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen K Brueggemann, RN, BSN</last_name>
      <phone>512-421-4108</phone>
      <email>Kristen.Brueggemann@USONCOLOGY.COM</email>
    </contact>
    <contact_backup>
      <last_name>Kaelyn Kappeler, CCRC</last_name>
      <phone>512-421-4234</phone>
    </contact_backup>
    <investigator>
      <last_name>Morris Groves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Ji, MD, MS</last_name>
      <phone>713-792-2400</phone>
      <email>xji@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Jacobs, BS, RN</last_name>
      <phone>713-792-2400</phone>
      <email>cjacobs@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Fred F Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karthik Sonty</last_name>
      <phone>801-587-5562</phone>
      <email>karthik.sonty@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brett Johnson</last_name>
      <phone>801-587-4429</phone>
      <email>brett.johnson@hci.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Howard Colman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takyee Tung</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>5578</phone_ext>
      <email>Takyee.Tung@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mariya Bakalets</last_name>
      <phone>416-946-4603</phone>
      <email>Mariya.Bakalets@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Gelareh Zadeh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain</keyword>
  <keyword>Central Nervous System (CNS) diseases</keyword>
  <keyword>Central Nervous System (CNS) neoplasms</keyword>
  <keyword>CNS</keyword>
  <keyword>conditionally replicative adenovirus</keyword>
  <keyword>DNX-2401</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>KEYTRUDA</keyword>
  <keyword>MK-3475</keyword>
  <keyword>SCH 900475</keyword>
  <keyword>lambrolizumab</keyword>
  <keyword>neoplasm, germ cell and embryonal</keyword>
  <keyword>neoplasm, granular and epithelial</keyword>
  <keyword>Alcyone</keyword>
  <keyword>Alcyone Lifesciences</keyword>
  <keyword>AMC</keyword>
  <keyword>cannula</keyword>
  <keyword>MEMS cannula</keyword>
  <keyword>DNX-2401 + pembrolizumab</keyword>
  <keyword>Delta-24</keyword>
  <keyword>Delta-24-RGD</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>anti-PD1/PD-L1</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>KEYNOTE-192</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Adenoviridae Infections</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Neoplasms, Nerve Tissue</mesh_term>
    <mesh_term>Neoplasms, Neuroepithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to share aggregate data at completion of study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

